New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors

Abstract

We have previously identified the pyrazolobenzothiazine scaffold as a promising chemotype against hepatitis C virus (HCV) NS5B polymerase, a validated and promising anti-HCV target. Herein we describe the design, synthesis, enzymatic, and cellular characterization of new pyrazolobenzothiazines as anti-HCV inhibitors. The binding site for a representative derivative was mapped to NS5B palm site I employing a mutant counterscreen assay, thus validating our previous in silico predictions. Derivative 2b proved to be the best selective anti-HCV derivative within the new series, exhibiting a IC50 of 7.9 μM against NS5B polymerase and antiviral effect (EC50 = 8.1 μM; EC90 = 23.3 μM) coupled with the absence of any antimetabolic effect (CC50 > 224 μM; SI > 28) in a cell based HCV replicon system assay. Significantly, microscopic analysis showed that, unlike the parent compounds, derivative 2b did not show any significant cell morphological alterations. Furthermore, since most of the pyrazolobenzothiazines tested altered cell morphology, this undesired aspect was further investigated by exploring possible perturbation of lipid metabolism during compound treatment.

Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold

“…The anti-NS5B RdRp activity of the compounds was evaluated by using a primer-dependent elongation assay as reported earlier [28]. In brief, the reaction buffer containing 20 mM Tris–HCl (pH 7.0), 100 mM Na-glutamate, 100 mM NaCl, 0.01% BSA, 0.01% Tween-20, 0.1 mM DTT, 5% glycerol, 20 U/mL of RNasin, 20 µM UTP, 1 µCi [α- 32 P]UTP, 0.25 µM polyrA/U 12 , 100 ng NS5BCΔ21 was incubated with compounds and the polymerase reaction was started by addition of 1 mM MnCl 2 in a final volume of 20 µl.…”

Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review

“…In recent years, various sulphonamide based isoxazolidines hybrids were synthesized and evaluated for in vitro HIV- Compounds 264 (EC 50 ¼ 8.1 mM and CC 50 ¼ >224 mM), 265 (EC 50 ¼ 4.8 mM and CC 50 ¼ >186 mM) ( Fig. 31) were identified as successful anti-HCV agents [187]. Kang et al designed and synthesized thiophene-pyrimidine analogues and evaluated their activity against a panel of mutant HIV-1 strains.…”

Bicyclic octahydrocyclohepta[ b ]pyrrol-4(1 H )one derivatives as novel selective anti-hepatitis C virus agents

“…The anti-RdRp activity of compounds were assessed by standard primer dependent elongation assay as described previously [23,24]. In brief, NS5B 1b was used as the source of polymerase in buffer …”